Is the "lead-in" with PEG-interferon/ribavirin still reasonable? (CROSBI ID 634127)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Vince, Adriana
engleski
Is the "lead-in" with PEG-interferon/ribavirin still reasonable?
Combination therapy with PEG-interferon (PEG-IFN), and ribavirin (RBV) has been the standard of care for genotype 1 CHC patients for 12 years. Many patients with different genotypes have been cured despite the well known side-effects. However the era of new direct acting antivirals that offer >90% efficacy, less side-effects and shorter duration of treatment has arrived. The main drawback is the extremely high-cost of those drugs. The 48-weeks treatment course with PEG-IFN+ribavirin is on average 5-8x cheaper then the cost of 12 weeks treatment with new direct acting antivirals without PEG-IFN (Sofosbuvir, ledipasvir, 3D combination). Shortenin the treatment course with PEG-IFN+ribavirin to 24 weeks this difference becomes even bigger. So, in lower-resource settings seems reasonable to look for interferon responders in naive patients.
PEG-interferon/ribavirin
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2015.
objavljeno
Podaci o matičnoj publikaciji
7. hrvatski kongres o urogenitalnim i spolno prenosivim infekcijama s međunarodnim sudjelovanjem - Knjiga sažetaka
Podaci o skupu
7. hrvatski kongres o urogenitalnim i spolno prenosivim infekcijama s međunarodnim sudjelovanjem
predavanje
08.05.2015-10.05.2015
Opatija, Hrvatska